Aim of the study: To study the effect of prescribing inhibitors of sodium glucose cotransporter type 2 (iSGLT-2) and inhibitors of dipeptidyl peptidase-4 (iDDP-4) on the parameters of carbohydrate metabolism in patients with type 2 diabetes.

Materials and methods: A prospective study included 80 patients with type 2 diabetes. The average age was 52.7 ± 3.78 years; diabetes experience - 8 years; BMI-30 ± 0.17; Hb1C-9.2 ± 0.4%; fasting glycemia –10.2 mmol/; eGFR-78 ml/min; TG-2.7 ± 0.44; total cholesterol-3.4 ± 0.72; MAU 32 ± 0.125. The patients were divided into 2 groups: group 1 - 30 patients with DN with impaired renal function and 30 patients with diabetic nephropathy without renal dysfunction in the presence of metformin + iSGLT- 2; 2 group of 30 patients with impaired renal function and 30 patients with diabetic nephropathy without impaired renal function on the background of metformin + iDPP-4.

Results: The study of the effect of the inclusion of drugs iSGLT-2 (group 1) and iDPP-4 (group 2) showed a positive dynamics of carbohydrate metabolism indicators in patients with type 2 diabetes. So if the initial indicators in the groups were comparable in terms of glycemic control indicators, then by the 3rd month of treatment there was a significant decrease in HbA1c in the 1st group of patients in relation to the 2nd group. The result of the correction performed within 3 months was the achievement of the state of compensation in the 1st group in 36.7%, and in the 2nd group in 28.3%, 48.3% of the patients of the 1st group were brought into the state of sub compensation and 31.7 % of patients of the 2nd group.

Conclusion: On the combination of metformin and INGLT-2, a larger number of patients managed to achieve the set goals of therapy with a lower risk of overt hypoglycemia, then this combination should be considered not only more effective.

Diabetes mellitus, diabetic nephropaty, hypoglycemic therapy

Alimov A.V., Khaidarova F.A., Berdykulova D.M., Alimova N.U., Sadikova A.S., Yuldasheva F.Z. Diabetes mellitus in the republic of uzbekistan: prevalence, morbidity according to statistical reports for the last 10 years. Bulletin of the Tashkent Medical Academy. - 2019. - No. 3. – P.. 8-13;

Mukhtarova Sh.Sh., Trigulova R.Kh., Ismailov S.I., Urmanova Yu.M., Influence of risk factors on the overall cardiovascular risk in patients with type 2 diabetes mellitus, Cadiological Journal of Uzbekistan, - 2020. - No. 1, - P. - 69-74;

International Diabetes Federation. IDF diabetes atlas. 9th ed. Brussels: International Diabetes Federation; 2019.

Doo Soo Jeon. Paradigm Shift for the Treatment of Type 2 Diabetes Mellitus in Patients with Cardiovascular Disease: Cardiologist's Perspective. Cardiovasc Prev Pharmacother. 2020 Jan;2(1):11-17.

Thomas MC, Brownlee M, Susztak K, Sharma K, Jandeleit, Dahm KA, Zoungas S, et al. Diabetic kidney disease. Nat Rev Dis Primers 2015;1:15018.

Bae JH, Kim S, Park EG, Kim SG, Hahn S, Kim NH. Effects of dipeptidyl peptidase-4 inhibitors on renal outcomes in patients with type 2 diabetes: a systematic review and meta-analysis. Endocrinol Metab (Seoul) 2019; 34: 80-92.

Makrilakis, Konstantinos. The Role of DPP-4 Inhibitors in the Treatment Algorithm of Type 2 Diabetes Mellitus: When to Select, what to Expect. International journal of environmental research and public health. 2019; vol. 16 (15) 2720.

Ide M, Sonoda N, Inoue T, et al. The dipeptidyl peptidase-4 inhibitor, linagliptin, improves cognitive impairment in streptozotocin-induced diabetic mice by inhibiting oxidative stress and microglial activation. PLoS One. 2020;15(2).

Kawanami D, Takashi Y, Takahashi H, Motonaga R, Tanabe M. Renoprotective Effects of DPP-4 Inhibitors. Antioxidants (Basel). 2021; 5;10(2):246.

Avogaro A, de Kreutzenberg S, Fadini G. Dipeptidyl-peptidase 4 inhibition: linking metabolic control to cardiovascular protection. Curr Pharm Des. 2014;20(14):2387-2394.

Davies MJ, D’Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2018;41:2669-701.

Molecular markers of tubulointerstitial fibrosis and tubular cell damage in patients with chronic kidney disease [Electronic resource] / S.Nakagawa [et al.] // PLoS One. – 2015. – Vol. 10, № 8. – e0136994.

Trujillo J.M., Nuffer W.A. Impact of Sodium-Glucose Cotransporter 2 Inhibitors on Nonglycemic Outcomes in Patients with Type 2 Diabetes // Pharmacotherapy. 2017. Vol. 37. № 4. Pp. 481-491. 25.;

Zaccardi F., Webb D., Htike Z., et al. Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis // Diabetes Obes. Metab., 2016. Vol. 18(8). Pp. 783-794.

Trujillo J.M., Nuffer W.A. Impact of Sodium-Glucose Cotransporter 2 Inhibitors on Nonglycemic Outcomes in Patients with Type 2 Diabetes // Pharmacotherapy. 2017. Vol. 37. № 4. Pp. 481-491. 25.;